HMGB1 and melanoma: The combination of BRAF inhibitor and MEK inhibitor led to persistent melanoma regression through immunomodulation.201 The combination of these two inhibitors induced the caspase-3 dependent GSDME lysis and the release of pro-inflammatory factors such as HMGB1.201 HMGB1 activates dendritic cells by interacting with toll-like receptor 4, thereby promoting anti-tumor T cell activity.